- Home
- EDIT vs SUPX Comparison
EDIT vs SUPX Comparison
Compare EDIT & SUPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- SUPX
- Stock Information
- Founded
- EDIT 2013
- SUPX 2021
- Country
- EDIT United States
- SUPX Singapore
- Employees
- EDIT N/A
- SUPX N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- SUPX
- Sector
- EDIT Health Care
- SUPX
- Exchange
- EDIT Nasdaq
- SUPX Nasdaq
- Market Cap
- EDIT 179.1M
- SUPX 198.5M
- IPO Year
- EDIT 2016
- SUPX 2024
- Fundamental
- Price
- EDIT $2.88
- SUPX $10.60
- Analyst Decision
- EDIT Buy
- SUPX
- Analyst Count
- EDIT 12
- SUPX 0
- Target Price
- EDIT $6.20
- SUPX N/A
- AVG Volume (30 Days)
- EDIT 3.5M
- SUPX 55.8K
- Earning Date
- EDIT 08-06-2025
- SUPX 08-15-2025
- Dividend Yield
- EDIT N/A
- SUPX N/A
- EPS Growth
- EDIT N/A
- SUPX N/A
- EPS
- EDIT N/A
- SUPX N/A
- Revenue
- EDIT $35,837,000.00
- SUPX $1,978,875.00
- Revenue This Year
- EDIT N/A
- SUPX N/A
- Revenue Next Year
- EDIT N/A
- SUPX N/A
- P/E Ratio
- EDIT N/A
- SUPX N/A
- Revenue Growth
- EDIT N/A
- SUPX N/A
- 52 Week Low
- EDIT $0.91
- SUPX $2.75
- 52 Week High
- EDIT $6.05
- SUPX $14.42
- Technical
- Relative Strength Index (RSI)
- EDIT 74.64
- SUPX N/A
- Support Level
- EDIT $2.48
- SUPX N/A
- Resistance Level
- EDIT $3.24
- SUPX N/A
- Average True Range (ATR)
- EDIT 0.25
- SUPX 0.00
- MACD
- EDIT 0.07
- SUPX 0.00
- Stochastic Oscillator
- EDIT 84.84
- SUPX 0.00
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About SUPX Super X AI Technology Limited Ordinary Shares
Super X AI Technology Ltd is a company that specializes in providing high-quality residential and commercial interior design solutions. Through its subsidiaries, SuperX aims to become a technology company dedicated to developing and delivering next-generation digital infrastructure solutions. It is committed to integrating smart technology into every aspect of its offerings, setting new standards for innovation and excellence in the industry.